Biocartis Group NV announces the recent publication of a new, large prospective study demonstrating that the Idylla EGFR Mutation Test (CE-IVD2) leads to the significant reduction of the time-to-treatment by 48% or on average 16.8 days faster than NGS testing for EGFR positive patients. This shows Idylla's potential to improve strategic treatment decisions within a multidisciplinary team for patients with advanced non-small cell lung cancer (NSCLC). The study was performed on 238 samples which were tested both using an NGS panel (Oncopanel) and the Idylla EGFR Mutation Test.
The study showed a concordance of 98.7% between the Idylla EGFR Mutation Test and the NGS panel. The lab turnaround time was faster for the Idylla EGFR Mutation Test by an average of 12.4 days. In the EGFR positive cohort, the Idylla EGFR Mutation Test led to a 48% reduction and on average 16.8 days faster turnaround time.
Furthermore, the study concludes that the Idylla EGFR Mutation Test could contribute to overall time and cost savings for patients if testing is implemented in a stepwise manner, where the Idylla EGFR Mutation Test and the PD-L1 IHC (Immunohistochemistry) test are performed first, and comprehensive yet more expensive NGS panel testing is only initiated in case of a negative Idylla EGFR Mutation Test. Such first-line use of Idylla EGFR Mutation Test is not only more cost-effective, but it also allows to obtain EGFR test results in the same time frame as the PD-L1 IHC test results, which is important as EGFR positivity may be a contra-indication for PD-1/PD-L1 therapy in NSCLC.